Horizon Therapeutics to Purchase Viela Bio for $3.1 Billion
- Acquisition adds treatment, expertise in autoimmune diseases
- AstraZeneca agrees to divest its 27% interest in Viela Bio
This article is for subscribers only.
Horizon Therapeutics Plc said it will purchase Viela Bio Inc. for about $3.1 billion to expand its portfolio and pipeline of treatments for rare diseases.
Horizon will acquire all of Viela Bio’s issued and outstanding shares for $53 each, according to a statement by the Lake Forest, Illinois-based company on Monday. That’s a 53% premium over Viela’s closing share price Friday. The transaction is expected to close by the end of the first quarter.